Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Double-masked, Randomised, Placebo-controlled Trial Investigating the Safety and Efficacy of Nicotinamide (NAM) to Slow Visual Field Loss in Adults With Open-angle Glaucoma

NCT05405868 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT05405868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05405868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Double-masked, Randomised, Placebo-controlled Trial Investigating the Safety and Efficacy of Nicotinamide (NAM) to Slow Visual Field Loss in Adults With Open-angle Glaucoma
Lead sponsor
University College, London
Phase
Phase 3
Overall status
Recruiting
Start date
January 18, 2024
Completion date
June 30, 2027
Enrollment
496 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, open-angle